Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02025621 · ClinicalTrials.gov registry record · Phase 3
Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
A Phase 3 study, sponsored by Tenax Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 882
- Enrollment target
NCT02025621 is a Phase 3 study that has completed, run by Tenax Therapeutics. The registered enrollment target is 882 participants.
The verdict
NCT02025621, a Phase 3 study, has completed, sponsored by Tenax Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 882 participants
- Enrollment target
Study Summary
A study to evaluate levosimendan compared with placebo in reducing the composite event rate of all-cause death, perioperative MI, need for new dialysis, or use of mechanical assist (IABP, LVAD or ECMO) in subjects with reduced ejection fraction undergoing cardiac surgery on cardiopulmonary bypass (CPB).
Interventions
- DRUG Placebo
- DRUG Levosimendan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 882 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02025621
The ClinicalTrials.gov registry entry for NCT02025621 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 882 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tenax Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02025621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02025621 about?
NCT02025621 is a clinical study titled "Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass". A study to evaluate levosimendan compared with placebo in reducing the composite event rate of all-cause death, perioperative MI, need for new dialysis, or use of mechanical assist (IABP, LVAD or ECMO) in subjects with reduced ejection fraction undergoing cardiac surgery on cardiopulmonary bypass (C...
What is the current status of trial NCT02025621?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 882 participants. The study started on 2014-07. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02025621?
The interventions under investigation include: Placebo (DRUG), Levosimendan (DRUG).
Who is sponsoring clinical trial NCT02025621?
This trial is sponsored by Tenax Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.